Info

Array BioPharma Inc. (Array) is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs. The Company’s drug development pipeline includes clinical candidates that are designed to treat patients afflicted with cancer, inflammatory diseases and pain. In addition, pharmaceutical and biotechnology companies collaborate with the Company to discover and develop drug candidates across a range of therapeutic areas. The Company has six wholly owned programs in its development pipeline: ARRY-797, a p38 inhibitor and pan-cytokine modulator for inflammation and for pain; ARRY-162, a mitogen-activated kinase (MEK) inhibitor for inflammation; ARRY-614, a p38/Tie 2 dual inhibitor for cancer and/or inflammation; ARRY-543, an ErbB family (EFGR/ErbB-2) inhibitor for cancer; ARRY-520, a kinesin spindle protein (KSP) inhibitor for cancer, and ARRY-380, an ErbB-2 inhibitor for cancer.(Source: 10-K)